Nanoencapsulated Drug-Carrying System for Photodynamic Antimicrobial Chemotherapy (PACT) by Kalapala, Gopala Krishna Murthy
Governors State University
OPUS Open Portal to University Scholarship
All Capstone Projects Student Capstone Projects
Summer 2011
Nanoencapsulated Drug-Carrying System for
Photodynamic Antimicrobial Chemotherapy
(PACT)
Gopala Krishna Murthy Kalapala
Governors State University
Follow this and additional works at: http://opus.govst.edu/capstones
Part of the Analytical Chemistry Commons
For more information about the academic degree, extended learning, and certificate programs of Governors State University, go to
http://www.govst.edu/Academics/Degree_Programs_and_Certifications/
Visit the Governors State Analytical Chemistry Department
This Project Summary is brought to you for free and open access by the Student Capstone Projects at OPUS Open Portal to University Scholarship. It
has been accepted for inclusion in All Capstone Projects by an authorized administrator of OPUS Open Portal to University Scholarship. For more
information, please contact opus@govst.edu.
Recommended Citation
Kalapala, Gopala Krishna Murthy, "Nanoencapsulated Drug-Carrying System for Photodynamic Antimicrobial Chemotherapy
(PACT)" (2011). All Capstone Projects. 23.
http://opus.govst.edu/capstones/23
Page 1 of 17 
 
Nanoencapsulated Drug-Carrying System for 
Photodynamic Antimicrobial Chemotherapy (PACT) 
By 
 
Gopala Krishna Murthy Kalapala 
 
 
 
MASTER’S PROJECT 
 
Submitted in partial fulfillment of the requirements 
 
For the Degree of Master of Science, 
With a Major in Analytical Chemistry 
 
Governors State University 
University Park, IL 60484 
 
2011 
Page 2 of 17 
 
Abstract 
The purpose of this study is to develop nanoparticulate drug-carrying systems 
that are capable of directly delivering photodynamic antimicrobial agents to treat 
patients with chronic wounds. Chronic wounds are considered as a pandemic health 
problem. Approximately 1% to 2% of the population in developing countries has 
experienced a chronic wound during their lifetime. In the United State States, according 
to the American Academy of Dermatology, the expense of treating chronic wounds 
constitutes over half of the total cost for all skin diseases, which exceeds $10 billion 
annually. For the last decade extensive basic science and clinical research in chronic 
wounds have suggested that pathogenic biofilm is the primary hindrance to the wound 
healing. Biofilms are highly organized, poly-species bacterial communities living within a 
protective extracellular matrix that they produce. They are difficult to detect and highly 
resistant to the host immune system or to antimicrobial elimination. Studies have shown 
that they can be up to 500 times more resistant to antibiotics than planktonic 
(unattached, freely living) cells.  
 Owing to bacterial species within biofilms being exceptionally resistant to many 
traditional therapies, Photodynamic Antimicrobial Chemotherapy (PACT) can provide an 
effective alternative for chronic wound treatment. The principle of PACT is derived from 
traditional photodynamic therapy, which is a technique that uses the combination of light 
and nontoxic drugs (photosensitizers) to destroy specific targeted cells. After the 
inactive, nontoxic drug is applied topically or injected, it can only be activated by 
irradiation with a certain wavelength of light. The light switches on the drug; once the 
drugs are activated they can produce highly reactive intermediates to destroy the 
targeted cells without damaging the surrounding healthy tissues. Once the irradiation is 
removed, the photosensitive drug will return to its stable, non-harmful state. The main 
advantage of PACT would be that it is very unlikely for bacteria to develop resistance to 
reactive oxygen species However, the main limitation of this technique would be the 
uptake kinetics of the photosensitizers in microorganisms. Therefore, the main objective 
of this study is to find a nanoencapsulated drug-carrying system that can easily 
penetrate into  the polymicrobial species habitat within biofilms. 
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INTRODUCTION 
In 2010, more than 7 million people suffered from chronic wounds and increases by 
10% annually.1 Approximately 80,000 people undergo amputation each year due to 
wounds that do not heal.2 Chronic wounds are a pandemic problem that can greatly 
affect a person's quality of life. The management and treatment cost billions of dollars a 
year globally. Most health professionals consider a wound to be chronic when it has not 
healed within 4 to 6 weeks. Surgical textbooks identify chronic wounds are those that do 
not heal in 3 months.3 Regardless the length of the time, wounds that do not heal 
through an orderly progression, halt in a stage dominated by inflammatory processes 
are considered chronic wounds.  
The most common chronic wounds are venous, diabetic, and pressure ulcers. Venous 
ulcers usually occur in the legs, accounting for about 70% to 90% of chronic wounds. 
The elderly are affected the most by these ulcers which penetrate deep into the skin 
and become infected easily. Occasionally, if a venous ulcer persists for a long time, skin 
cancer could develop at the edge.4-6  In the United States, 8.3% of the population is 
diabetic and each year about 65,700 non-traumatic lower-limb amputations are 
performed in people with diabetic ulcers. In addition, there are about 2.5 million 
Americans currently hospitalized who are suffering from pressure ulcers (bed-sores).6,7 
The statistical data shows a great need for the treatment of chronic wounds. There are 
biological and physiological reasons for wounds that are not healing. A primary barrier 
to healing is the continuing influx of poly-morphonuclear leukocytes (PMNs, a category 
of white blood cells) from the host blood circulatory system to the open wounds. 
Activated PMNs release cytotoxic enzymes and inflammatory mediators that can 
damage host tissues.8-10 Owing to this continuous influx of PMNs, the healing and the 
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destructive processes within the chronic wounds are imbalanced; and the main reason 
for this distress is the presence of biofilms.  
Biofilms are highly structured groups of pathogenic microbes living within a protective 
extracellular matrix that they produce. The extracellular polymeric substance provides 
physical protection to the microorganisms from its environment. Biofilms in chronic 
wounds are difficult to detect and highly resistant to the host immune system and 
antibiotic elimination.  Presently, the most common management of biofilm infections is 
physical removal of the biofilm called surgical debridement.11 This procedure involves 
aggressive removal of massive amount of necrotic tissues. Theoretically it would be the 
preferred method, however, due to the invasive nature it is not always the best option.  
The life threatening dangers to the patient are tremendous such as anesthesia risk, 
bleeding, sepsis, and bacteremia.11.12  
In order to overcome problems associated with the treatment of chronic wounds, non-
invasive Photodynamic Antimicrobial Chemotherapy (PACT) can provide an alternative 
method to heal chronic wound.  The principle of PACT is the same as that of traditional 
photodynamic therapy. It is a non-intrusive technique that uses a combination of light 
and nontoxic drugs (photosensitizers) to destroy targeted cells. After the inactive, 
nontoxic drug is applied topically or injected, it can only be activated by irradiation with a 
certain wavelength of light. Once the drugs are switched on by light, they can produce 
highly reactive intermediates to destroy the targeted cells without damaging the 
surrounding healthy tissues. Once the irradiation is removed, the photosensitive drug 
will return to its stable, non-harmful state.  
The main limitation of this technique would be the uptake kinetics of the photosensitizer 
in microorganisms. In general, neutral, anionic, and cationic photosensitizers can 
efficiently eliminate Gram-positive bacteria.13 only hydrophilic cationic photosensitizers 
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can kill Gram-negative bacteria. The porous cell wall of Gram-positive bacteria allows 
most photosensitizers to cross. However, the cell envelope (outer membrane) of Gram-
negative bacteria forms an effective permeability barrier between the cells and its 
environment.14 This has led to intensive research on particulate delivery systems to 
overcome this situation. Studies have shown that using a nanoemulsion as a carrier for 
biomedical applications can improve efficacy in solubilizing, protecting, and targeting 
drugs for specified delivery.15-17 Therefore one can anticipate such an approach to 
greatly advance current chronic wound diagnostics and treatments. 
 EXPERIMENTAL METHODS 
Nanoemulsion 
The photosensitizers (Active Pharmaceutical Ingredient) used in the study are 
mostly hydrophobic and less permeable to cross the cell barrier. To intervene this, a 
nanoemulsion of drug is being prepared for optimal drug delivery. In general, neutral, 
anionic, and cationic photosensitizers can efficiently eliminate Gram-positive bacteria. 
Only hydrophilic cationic photosensitizers can kill Gram-negative bacteria. The porous 
cell wall of Gram-positive bacteria allows most photosensitizers to cross. However, the 
cell envelope (outer membrane) of Gram-negative bacteria forms an effective 
permeability barrier between the cells and its environment. This has led to intensive 
research on particulate delivery systems to overcome this situation. Many studies have 
shown that using nanoemulsions or nanoparticles as carriers for biomedical applications 
can improve efficacy in solubilizing, protecting, and targeting microorganisms for 
specified delivery. Therefore one can anticipate that our approach can greatly advance 
current chronic wound treatment. 
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Formulation PACT-3A: The first generation porphyrins tested for photodynamic 
therapy were based on chemically modified natural hematoporphyrins. They possessed 
certain limitations such as weak absorption in the phototherapeutic window as well as 
poor specificity toward malignant and healthy tissues. The second generation of 
photosensitizers was mainly based on the engineered, synthetic, and semi synthetic 
porphyrins with various expanded substituents at the pyrrol rings and the methylene 
bridges.  The optical properties for therapy have  improved in the second 
generation photosensitizers but delivery to the target tissue is still a passive process.  
In this study, several approaches have been taken in order to improve the direct 
targeting and to increase reactive species generation of PACT agents. The 
photosensitizers together with a direct delivery mechanism are known as the third 
generation of photosensitizers or smart drugs. Also, owing to most porphyrin and 
phthalocyanine derivatives not being water soluble, oil-in-water nanoemulsion and 
nanoparticle formulations have been developed to promote drug delivery.  
Formulation PACT-3A-1:  
I. Dissolve 30 mg copper Phthalocyanine (CuPc) and 4.0 mL of surfynol- 465 in 10 
mL of ethyl acetate (organic phase) over low heat with constant stirring. 
II. Dissolve 270 mg high molecular weight PEG (Mr > 2000 g/mol) in 50 mL of water 
(water phase).  
III. Add the organic phase into the water phase while vigorously stirring until all the 
ethyl acetate has evaporated. Sonicate for 15 minutes. 
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Formulation PACT-3A-2:  
I. Dissolve 6 mg of copper Phthalocyanine (CuPc) and 2.0 mL of surfynol 465 in 10 
mL of ethyl acetate (organic phase) over low heat with constant stirring. 
II. Dissolve 0.2 g of poloxamer- 407 in 20 mL of water (water phase).  
III. Add organic phase into water phase while vigorously stirring over low heat until 
all the ethyl acetate has evaporated.  
IV.   The solution is then degassed to remove the foam. 
V.  Sonicate for 15 minutes. 
Formulation PACT-3A-3:  
I. Dissolve 6 mg (5.5 µmole) of copper Phthalocyanine (CuPc) and 2.0 mL of 
surfynol- 465 in 20 mL of ethyl acetate (organic phase) over low heat with 
constant stirring. 
II. Dissolve 11 µmole of o-(octadecylphosphoryl)choline in 20 mL of water (water 
phase).  
III. Add organic phase into water phase while vigorously stirring. Keep adding water 
while stirring and bring the volume to 100 mL.   
IV. Keep stirring overnight until all the ethyl acetate has evaporated and bring the 
volume down to 20 mL.   
IV.   The solution is then degassed to remove the foam. 
V.  Sonicate for 15 minutes. 
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Formulation PACT-3A-4:  
I. Dissolve 3 mg of riboflavin and 0.168 g of PLGA in 10 mL of ethyl acetate 
(organic phase) under low heat with constant stirring. 
II. Add 1 mL of Triton X– 100 (HLB 11.6) t0 10 mL of PBS (water phase).  
III. Add organic phase into water phase while vigorously stirring over low heat until 
all the ethyl acetate has evaporated.  
IV.  Sonicate for 15 minutes. 
Stabilizer and Thickening Agent 
PEG and poloxamer are well known stabilizers; therefore, no additional stabilizer 
is needed in some of our formulations. Carbomer, a synthetic high molecular weight 
polymer of acrylic acid will be used as an additional stabilizer and also as a thickening 
agent to increase the viscosity of all the formulations.  
Singlet Oxygen Study 
Singlet oxygen determination has been carried out by UV-Vis spectroscopy 
(Ocean Optics) with loggerpro-3.6.0 Vernier software. The 9,10-anthracene dipropionic 
acid (ADPA) photo-bleaching method is used to confirm singlet oxygen generation. 
ADPA is easily converted to a photo inactive endoperoxide by singlet oxygen. An ADPA 
solution in deuterium oxide (D2O) is used as the singlet oxygen acceptor. Mixed 
solutions of the photosensitizer and ADPA are irradiated with visible light. The reaction 
progress is monitored by recording the decrease of the 400 nm absorption peak of 
ADPA verses irradiation time. The intensity of ADPA absorption decreased as the 
irradiation time increased, which indicates the generation of singlet oxygen. 
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DNA Study 
Drug formulation at different concentrations, pUC19 Plasmid (120 µM), NaCl (5 
mM) are added to transparent eppendorf micro tubes. A uniform volume of 20 µL is 
maintained in all tubes. The tubes are incubated in the dark for 0.5 h with subsequent 
irradiation of the light samples under visible light in the photoreactor ( 2.8 x 10-3 W/cm2 ; 
5.0 J/cm2) for 0.5 h.The dark and light samples are loaded into the gel with gel loading 
solution (4 µL) and gel electrophoresis (90 V; 1.5 h)  is carried out using agarose (2.0%)  
stained with ethidium bromide in 1X TAE running buffer.  The gel is imaged on Gel Doc 
200 transilluminator (Bio-Rad, Hercules, CA)  with the supercoiled DNA at position 2 
and the nicked DNA at position  1. The degree of photocleavage is estimated by the 
integration of the image intensity at position 1 and position 2 by Quantity One Analysis 
system software (Bio-Rad, Hercules,CA). 
Cell and Bacteria Study 
Human skin fibroblasts (Hs-27) from the American Type Culture Collection, cell 
line CRL-1634 (Manassas, VA) are used in the cell study. The cells were cultured in 
Dulbecco’s Modified Eagle Media (10% fetal bovine serum, 50 µg/mL gentamicin, 4.5 
mg/mL glucose, and 4 mM L-glutamine).  The cells are cultured in BD-Biocoat (60 mm) 
culture dishes (at 5.0% CO2 at 37oC in the incubator). The media is washed away from 
the culture plates using 1X phosphate buffer for the assesment of  cytotoxicity and 
photocytotoxicity of the nanoparticles. Uniform volume of nanoemulsion (test), 1X PBS 
(blank), and placebo (control) are added to the culture dishes. The culture dishes are 
incubated for 1.0 h in the dark and in visible light seperately for photocytotoxicity. The 
supernant  from the culture dishes are decanted and washed with 1X PBS. The cells 
are lysed using cell lysis solution (20 µM sodium laurylsarcosine solution) for 
approximately 1.0 h on a shaker. The protein content from the lysed culture dishes are 
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quantified using BCA Protein Assay (Thermopierce). The culture dishes are incubated 
for an hour and the absorbance intensity of the purple color complex formed is observed 
at 570 nm  in Biotek ELx800 micro plate reader for the dark and light samples. 
E coli (Gram negative)  and S. aureus (Gram positive) are cultured in petri dishes 
with nutrient broth culture media. The nanoemulsion is added to the bacterial culture 
and incubated for an hour. Half of the culture remains in the dark and the other half is 
irradiated for 0.5 h.  The absorbance readings of both the irradiated and dark samples 
are observed on Biotek Epoche Absorbance Plate reader. 
RESULTS 
Nanoparticles 
 
 
 
 
 
 
 
In the above figure, the blue line represents the typical UV-Vis spectrum of 
aqueous Vitamin B12. it shows a π to π* transition peak at 272 nm, a n to π* transition 
peak at 370 nm and a MLCT peak at 570 nm. The red line from the above figure shows  
decreasing absorption intensity compared to the blue line at the same concentration (50 
µM) of Vitamin B12. The graph clearly indicates that vitamin B12 has been entrapped 
 
Figure 1 
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inside the double coated nanoparticles. The enhancement of UV absorption below 300 
nm  is due to the absorbtivity of phophocholine which has a λmax of 225 nm.  
 
 
 
 
 
 
 
 
 
 
 
Above figure shows Vitamin B2 is encapsulated inside palmitic acid nanoparticles. It is 
well known that Vitamne B2 (riboflavin) is not very soluable in water, it reaches the 
saturation at 200 µM. The red line from above graph shows the fluorescence of 200 µM 
riboflav in aqueous solution.  The green line is arbitrally created to show the intensity of 
800 µM riboflavin in water. The dark blue line shows 800 µM riboflavin in ethyl acetate. 
The light blue line shows 800 µM riboflavin encapsulated inside the nanoparticles then 
suspended in water.  The hypochromic effect of the light blue linecompared to the dark 
blue line (both 800 µM) indicates the increasing of hydrophilicity. Compare the green 
 
Figure 2 
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line and the light blue line, it is evident that riboflavin has been encapsulated inside the 
nanoparticles.  
 
 
 
 
 
 
 
 
 
 
Above figure shows copper phthalocyanine (CuPC) entrapped inside surfynol-
poloxamer (dark blue line) and surfynol-phosphocholine (green line) double coated 
nanoparticles. CuPc is a hydrophobic molecule, when dissolved in a non-polar solvent 
such as ethyl acetate, the electronic absorption spectra shows only a strong π to π* 
peak (the light blue line). Electronic transitions n to π* and MLCT start to take place only 
when the polarity of the solvent increases. DMSO has a polarity of 7.2, the inset graph 
shows when CuPc dissolved in DMSO, the absorption spectra starts to show a MLCT 
band due to the increased excited state dipole moment. The electronic absorption 
shows very different transitions in the visible region (the dark blue and green lines from 
the above figure) when CuPc nanoparticles suspended in water (polarity = 10.2) than 
when it is in the non-polar solvent (the light blue line).  
 
 
Figure 3 
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Above figure shows TEM of CuPc encapsulated nanoparticles. (A) Indicated 
Magnification is X25000 and the Total Magnification is X28800. (B) Indicated 
Magnification is X60000 and the Total Magnification is X69900. 
Singlet Oxygen Study 
Singlet oxygen study was also preformed on riboflavin to ascertain its generation over 
time. Figure 3 shows that after only 0.25 h of irradiation, riboflavin is able to produce a 
significant amount of singlet oxygen. The sensor used in the singlet oxygen study is 
9,10-anthracene dipropionic acid (ADPA). Our result has shown that riboflavin is an 
excellent source of producing reactive oxygen species when irradiated with low energy 
visible light. 
 
 
 
 
 
 
 
 
Figure 4 
Figure 5 
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Above figure shows the absorption intensity of ADPA (at 400 nm, in the presence of 
CuPc) decreased as the irradiation time increased indicates ADPA was converted to an 
endoperoxide derivative by singlet oxygen.  
 
Table 1. LD50 (lethal dose 50 in mg/Kg) of Riboflavin and Phylloquinone in both dark 
and irradiated conditions . Acute oral systematic toxicity of both was cited from the 
official MSDS. 
Cytotoxicity and Photocytotoxicity 
The cytotoxicity and photocytotoxicity study was executed using human fibroblast skin 
cells. Table 1 shows that both riboflavin and phylloquinone have no toxic effect on 
human skin cells in the dark. There is a slight adverse effect when the riboflavin and 
phylloquinone is irradiated with light, but these numbers are much lower compared to 
the acute oral toxicity obtained from the MSDS. Furthermore, the reactive oxygen 
species that are formed when irradiated with visible light have such a short lifetime and 
can not travel far, so only those cells which are irradiated with light will be effected in the 
end.  
Bacteria Study 
The bacterial study of riboflavin and phylloquinone was conducted using E. coli and S. 
aureus. A concentration as low as 85 mg/Kg of riboflavin can cause 50% fatality of 
bacteria after an hour of incubation followed by 0.5 h of irradiation with low intensity 
light, ~5.0 J/cm2. These results were compared with the acute oral toxicity of riboflavin 
and phylloquinone obtained from the official MSDS. Table 1 confirms that at a low 
 Human Skin E.coli S. Aureus Acute Oral 
  Dark Irradiated Dark Irradiated Dark Irradiated  
Riboflavin No 
 
2,170 ± 110 197 ± 
 
85 ± 4.20 275 ± 
 
117 ± 
 
>10,000 
Phylloquinone No 
 
18,700 ± 
 
1,100 ± 
 
423 ± 
 
3,270 475 ± 
 
25,000 
Page 15 of 17 
 
concentration, riboflavin and phylloquinone are able to eradicate bacteria upon 
irradiation.  S. Aureus is a gram-positive bacteria that can be easily penetrated by 
photosensitizers due its porous cell wall. However, E. Coli is a gram-negative bacteria 
which has a outer membrane that is hard to penetrate. Our results indicate our 
nanoemulsion can easily pass through the bacterial membrane and release the 
photosensitizers. 
DISCUSSION  
We have shown that photodynamic antimicrobial chemotherapy (PACT) has the 
potential to represent an alternative antibacterial, antifungal, and antiviral treatment for 
drug-resistant organisms. Non-toxic vitamins such as riboflavin and phylloquinone can 
produce singlet oxygen and free radicals upon irradiation. Our data has shown that 
riboflavin not only has a great DNA binding constant (Kb > 104 M-1), it can also cleave 
bacterial DNA under the irradiation of the visible light (λ > 395 nm). Nanoemulsion also 
has proven to be an effective way for drug delivery. Their photobiological properties and 
phototoxicity towards prokaryotic cells still needs to be investigated further. In addition, 
spin-off applications of this work would offer opportunities for other environmental 
friendly uses such as bioremediating hazardous waste sites, biofiltering industrial water, 
and forming biobarriers to protect soil and groundwater from contamination.  
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